Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 037 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 075 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 037 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 075 IN DEXTROSE 5 IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and normal nerve conduction and muscle contraction, including cardiac muscle. Dextrose provides a source of calories and may prevent ketosis.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid composition, nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration, with dextrose being metabolized to carbon dioxide and water, supplying energy.
Intravenous infusion of potassium chloride 0.037% in dextrose 5% at a rate not exceeding 10 mEq/hour of potassium and a maximum concentration of 40 mEq/L in peripheral veins; dose determined by serum potassium level and clinical need, typically 20-40 mEq per day for mild depletion.
Intravenous administration at a rate not exceeding 10 mEq/hour of potassium chloride; typical adult dose is 20-40 mEq per day administered as an additive to dextrose 5% solution, titrated to serum potassium levels.
None Documented
None Documented
Potassium has a complex disposition; the distribution between intracellular and extracellular compartments affects half-life. In normal renal function, the serum potassium half-life is approximately 4-6 hours after a dose, but this is not a true terminal half-life due to extensive tissue buffering. The body's total potassium turnover half-life is around 25-30 hours. In patients with renal impairment, half-life is prolonged proportionally to creatinine clearance.
Potassium has a biphasic elimination: distribution half-life ~1 hour, terminal elimination half-life ~12 hours in normal renal function. Clinical context: Half-life extends significantly in renal impairment, requiring dose adjustment.
Potassium is primarily excreted renally (>90%) with about 10% excreted in feces via gastrointestinal secretion. Minimal excretion occurs through sweat. Renal handling involves glomerular filtration, proximal tubular reabsorption, and potassium secretion in the distal tubule and collecting duct regulated by aldosterone. Excretion is not linear and depends on potassium balance, renal function, and hormonal influences.
Potassium is primarily excreted renally (approximately 90%) via glomerular filtration and distal tubular secretion. Minor fecal elimination accounts for ~10%. Renal excretion is influenced by aldosterone, acid-base status, and potassium intake.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement